Hospira, Inc. Taxotere Ruling A Positive For Shareholders

Delaware District Court ruling on the Taxotere patents is seen as a meaningful positive for Hospira, Inc. HSP according to a J.P. Morgan research report. J.P.Morgan writes, "While we anticipate temporary restraining order/preliminary injunction requests from Sanofi, we believe this ruling could pave the way for Hospira's generic entry in November 2010. Along these lines, we are raising 2011-2013 estimates for the company to account for generic Taxotere ($1.25 bn LTM IMS branded sales) and reiterate our OW rating." Price Target for HSP is being raised from $62.00 to a $66.00 a share. HSP shares closed Monday at $57.10.